Clinical trials: sponsored by AstraZeneca
Gastrointestinal Endoscopy, Gastrointestinal Polypectomy
Dose Rate Range Finding Study of Propofol for minimal-to Moderate Sedation on Upper & Lower Endoscopic Tests
Phase IIB study to find the optimal dose rate range of propofol to maintain minimal-to-moderate sedation for diagnostic gastrointestinal endoscopy and gastrointestinal polypectomy.
- Trial name
- NCT01189604
- Testing
- ICI35,868 (propofol)
- Where
- 2 sites in Japan
- Volunteers
- 123 people
- Sponsor
- AstraZeneca
Schizophrenia
Study of the Efficacy and Safety of Quetiapine Fumarate Extended Release (Seroquel XR)
This is an 8-week, multi-centre, Open-label, non-comparative study to evaluate the efficacy and safety of Quetiapine XR with daily dose 400mg-800mg used as mono-therapy in the treatment of acute schizophrenic patients.
- Trial name
- QUENCH (NCT00779506)
- Testing
- Quetiapine Fumarate XR
- Where
- 7 sites in South Korea
- Volunteers
- 96 people
- Sponsor
- AstraZeneca
Stable Coronary Artery Disease
A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-responders
The purpose of this study is to see how Ticagrelor, a new oral reversible anti-platelet medication, affects platelets. Anti-platelet agents are medications that block the formation of blood clots by preventing the clumping of…
- Trial name
- RESPOND (NCT00642811)
- Testing
- Ticagrelor, Clopidogrel, Aspirin
- Where
- 10 sites in United States, Canada and 2 more
- Volunteers
- 98 people
- Sponsor
- AstraZeneca
Rheumatoid Arthritis
A Proof of Concept and Dose Ranging Study in Patients With Rheumatoid Arthritis
This study is being carried out to investigate if AZD5672 is effective in treating Rheumatoid Arthritis (RA) and if so how it compares to placebo (a substance which does not have any action) and etanercept (a medicine already…
- Trial name
- ESCAPE (NCT00713544)
- Testing
- AZD5672, Etanercept
- Where
- 49 sites in Bulgaria, Colombia and 12 more
- Volunteers
- 373 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
An 18 Week Efficacy and Safety Study of Saxagliptin and Metformin XR Combination in Subjects With Type 2 Diabetes
The purpose of this study is to compare reduction in A1C for subjects taking Saxagliptin and Metformin XR vs. uptitrated Metformin XR.
- Trial name
- SCORE (NCT00960076)
- Testing
- Saxagliptin, Metformin XR
- Where
- 35 sites in United States, Colombia and 3 more
- Volunteers
- 282 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
Evaluate Saxagliptin in Adult Indian Patients With Type 2 Diabetes Inadequate Glycemic Control
Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to evaluate the efficacy and safety in adult Indian patients with inadequate glycaemic control with diet and…
- Trial name
- NCT00918879
- Testing
- Saxagliptin
- Where
- 9 sites in India
- Volunteers
- 213 people
- Sponsor
- AstraZeneca
Atrial Flutter
Cardiac Electrophysiological Study
The purpose of the study is to measure the effects of AZD1305 on cardiac electrophysiological properties and intracardiac pressures
- Trial name
- NCT00616629
- Testing
- AZD1305
- Where
- 13 sites in Denmark, Finland and 2 more
- Volunteers
- 55 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
Evaluate Efficacy and Safety of Saxagliptin in Adult Patients With Type 2 Diabetes Inadequate Glycemic Control
Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to evaluate the efficacy and safety in adult patients with inadequate glycaemic control with diet and…
- Trial name
- NCT00698932
- Testing
- Saxagliptin
- Where
- 30 sites in China, India and 2 more
- Volunteers
- 568 people
- Sponsor
- AstraZeneca
Diabetes Mellitus
Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal Disease
The purpose of this study is to evaluate the effects of Crestor (rosuvastatin) and (Lipitor) atorvastatin on urinary protein excretion over 1 year in patients with Type 1 or 2 diabetes with moderate proteinuria and…
- Trial name
- PLANET 1 (NCT00296374)
- Testing
- Rosuvastatin, Atorvastatin
- Where
- 116 sites in United States, Argentina and 9 more
- Volunteers
- 353 people
- Sponsor
- AstraZeneca
Hypertension
Atacand Dose Ranging in Hypertensive Pediatric Subjects 1 Year to Less Than 6 Years of Age
This is a dose ranging study of candesartan cilexetil in hypertensive pediatric subjects ages 1 to less than 6 years of age. It employs a double blind, randomized, dose ranging design intended for conduct as a multicenter trial.
- Trial name
- NCT00244621
- Testing
- candesartan cilexetil (Atacand)
- Where
- 38 sites in United States, Belgium and 8 more
- Volunteers
- 95 people
- Sponsor
- AstraZeneca
Hypercholesteremia
Rosuvastatin in the Long-term Treatment of Hypercholesterolaemic Subjects With Coronary Heart Disease
The primary objective of this study is to evaluate that 76 weeks of treatment with rosuvastatin calcium 2.5-20 mg results in no progression of coronary artery atherosclerotic volume as measured by intravascular ultrasonography…
- Trial name
- NCT00329160
- Testing
- Rosuvastatin, HMG CoA inhibitor
- Where
- 27 sites in Japan
- Volunteers
- 214 people
- Sponsor
- AstraZeneca
Familial Hypercholesterolemia
PLUTO: Pediatric Lipid-redUction Trial of rOsuvastatin
The primary objective of this study is to determine the efficacy of once-daily rosuvastatin in reducing LDL-C in children and adolescents aged 10-17 years with HeFH from baseline (Day 0) to the end of the 12-week double-blind…
- Trial name
- NCT00355615
- Testing
- Rosuvastatin
- Where
- 20 sites in United States, Canada and 3 more
- Volunteers
- 173 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
A Diabetes Study to Treat A Population Previously Not at Target
This study will assess if customizing the start dose of rosuvastatin appropriate for the degree of LDL-C reduction required, would achieve LDL-C target of ≤ 2.0 mmol/L quickly with either no titration or just one titration step…
- Trial name
- ADAPT (NCT00747149)
- Testing
- Rosuvastatin
- Where
- 84 sites in Canada
- Volunteers
- 598 people
- Sponsor
- AstraZeneca
Metabolic Syndrome
Effect of Crestor (Rosuvastatin) on Lipid Levels in Patients With Metabolic Syndrome
The primary objective is to evaluate the efficacy of rosuvastatin therapy on plasma lipid profile (Low Density Lipoprotein (LDL), High-Density Lipoprotein (HDL), total cholesterol, triglyceride) in patients with metabolic…
- Trial name
- EFFORT (NCT00815659)
- Testing
- rosuvastatin
- Where
- 6 sites in Turkey (Türkiye)
- Volunteers
- 97 people
- Sponsor
- AstraZeneca
Non-diabetic Nephropathy With Hypertension
ARIA (Atacand Renoprotection In NephropAthy Pt.)
To determine the effective dose of candesartan cilexetil for reduction of urinary protein excretion in hypertensive patients with non-diabetic chronic kidney disease with baseline urinary protein/creatinine ratio between 500mg/g…
- Trial name
- PCR (NCT00573430)
- Testing
- Candesartan Cilexetil, Candesartan Cilexetil 32mg
- Where
- South Korea
- Volunteers
- 128 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Safety/Tolerability Study With AZD1236 in Chronic Obstructive Pulmonary Disease (COPD) Patients
The primary aim of this study is to investigate the tolerability and safety of AZD 1236 compared with placebo ("inactive substance") in COPD patients by assessment of Adverse Events, vital signs and laboratory safety assessments.
- Trial name
- CERA (NCT00758459)
- Testing
- AZD1236
- Where
- 14 sites in Bulgaria, Finland and 3 more
- Volunteers
- 74 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
The Study Will Evaluate the Effect of AZD9164 in Patients With Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease (COPD) is a chronic respiratory condition with deteriorating lung function over the years. Patients with COPD experience symptoms of shortness of breath, cough and sputum production.
- Trial name
- LaCrossE (NCT00939211)
- Testing
- AZD9164, Tiotropium
- Where
- 3 sites in Sweden
- Volunteers
- 25 people
- Sponsor
- AstraZeneca
Hypertension
Study to Characterize the Long-term Clinical Experience of Atacand in Hypertensive Children Ages 1 to<11 Years (Hypertension in Pediatrics)
The HIP study is designed to follow the clinical experience of young hypertensive children receiving candesartan cilexetil (Atacand) who are between the ages of 1 and less than 11 years old.
- Trial name
- HIP (NCT00690612)
- Testing
- candesartan cilexetil
- Where
- 13 sites in Belgium, France and 4 more
- Volunteers
- 35 people
- Sponsor
- AstraZeneca
Metabolic Syndrome X
ROMEO (Rosuvastatin in Metabolic syndrOme)
The primary objective of this study is to compare the effect of rosuvastatin 10mg with atorvastatin 10mg after 6 weeks of treatment in the ratio of ApoB/ApoA1 in subjects with metabolic syndrome.
- Trial name
- NCT00395486
- Testing
- Rosuvastatin, Atorvastatin
- Where
- 3 sites in South Korea
- Volunteers
- 258 people
- Sponsor
- AstraZeneca
Left Ventricle Function
Investigate the Effect of AZD1305 on Patients With Left Ventricular Dysfunction
To explore if AZD1305 compromises left ventricular performance in patients with left ventricular dysfunction
- Trial name
- NCT00748982
- Testing
- AZD1305
- Where
- Sweden
- Volunteers
- 16 people
- Sponsor
- AstraZeneca